Full-Time

Quality Control Data Reviewer 2

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$72k - $89.9k/yr

+ 401(k) matching contributions

Albany, NY, USA

In Person

Bachelor's, Master's

Category
Manufacturing Quality & Test (1)
Required Skills
GMP

Get referred to Curia

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Chemistry or a related field and a minimum of three years of relevant industry experience, or a Master’s degree and one year of relevant experience.
  • Knowledge of analytical instrumentation such as XRPD, PSD, DSC, TGA, UV, FTIR, HPLC, and GC.
  • Experience working in a cGMP or GLP pharmaceutical industry environment is preferred.
  • Must pass a background check.
  • Must pass a drug screen.
  • May be required to pass Occupational Health Screening.
Responsibilities
  • Review and approve primary analytical data according to cGMP guidelines.
  • Review quality control testing for compliance with internal standard operating procedures and specifications.
  • Assist in technical data review of raw data generated for compendial testing, including USP/NF, EP, and JP, as well as Curia in-house and client methodologies, to ensure data accuracy and integrity.
  • Collaborate with laboratory personnel on data review for cGMP compliance and data integrity.
  • Ensure all tests comply with cGMP requirements and the company’s standard operating procedures.
  • Provide training to new hires as needed and attend internal and external training on related subjects, cGMP compliance, data integrity, new techniques, and procedures.
  • Report personnel performance to appropriate management, highlighting areas and individuals needing improvement as well as those exceeding expectations.
  • Author, review, and approve Quality Management System documents, including change controls, standard operating procedures, deviations, and CAPAs.
  • Support raw material release and GMP production suite commissioning activities when necessary.
  • Perform quality assurance cleaning verification and inspection activities when required.
  • Oversee implementation of new test methods to maintain compliance with cGMP and standard operating procedure requirements.
  • Provide guidance to analysts, supervisors, and quality personnel to promote compliance for customers.
  • Support Quality initiatives when necessary.
Desired Qualifications
  • Experience working in a cGMP or GLP pharmaceutical industry environment.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.